Dr. Eklov took his current role as CEO for Dipharma Inc. in 2021. During his tenure, Dipharma Inc. designed and built a state-of-the-art CGMP Kilolab, and successfully navigated its first FDA inspection for a commercial API. He joined the Company as a research scientist in 2007, after receiving his Ph.D. from the University of Minnesota and a post-doctoral appointment at the University of Illinois, where he trained in synthetic organic chemistry.